In wake of Eli Lil­ly set­back, Mer­ck KGaA's lead­ing BTK drug for au­toim­mune dis­ease clears PhI­Ib hur­dle

What kind of fu­ture awaits Bru­ton’s ty­ro­sine ki­nase drugs in au­toim­mune con­di­tions?

A fa­mil­iar play­er in hema­tol­ogy, which at­tract­ed the first big round of in­vest­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER